Shanghai MicroPort MedBot (Group) Co., Ltd.
上海微创医疗机器人(集团)股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT — TOUMAI COMMERCIAL INSTALLATIONS EXCEEDING 100 UNITS WORLDWIDE

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company (the "**Shareholders**") and potential investors the updates on the latest business development of the Group.

In terms of cumulative orders, according to the preliminary internal statistics of the Group, the cumulative order volume of the Group's laparoscopic, orthopedic and vascular interventional core products has exceeded 230 units. Among them, the core product, Toumai Laparoscopic Surgical Robot ("**Toumai**") has accumulated over 160 commercial orders worldwide, including nearly 120 new orders secured this year. According to the public statistics, Toumai's global order volume in 2025 has ranked among the top two globally.

In terms of commercial installations, as of the date of this announcement, the Group's products have collectively achieved commercial installations of over 150 units under the aforementioned integrated orders. Among them, the commercial installations worldwide of Toumai have exceeded 100 units. All 100 installations have obtained installation and acceptance reports signed by the customers. All of these transaction arrangements satisfy the Company's revenue recognition policy, and the corresponding revenues have been recognized. The Company's revenue recognition policy complies with HKFRS Accounting Standards and industry practices.

Toumai has become the first domestic laparoscopic surgical robot to achieve commercial installations of 100 units, which not only proves that it has achieved system reliability and clinical stability at an industry infrastructure level, but also marks a comprehensive leap in key systems such as quality compliance, production processes, engineering validation, system delivery, clinical adaptation and full-process assurance capabilities.

In the domestic markets, Toumai has made breakthroughs in the top public hospitals and high-end non-public hospitals market, among the hospitals where Toumai has been installed, the proportion of top 100 hospitals has reached 23%, and the proportion of Grade-IIIA hospitals exceeds 90%. Toumai has progressively established a high-quality installation landscape with clinical value-driven and professional capability accumulation as its core. Leveraging the Group's independently innovated remote technology capabilities, hospitals at all levels have implemented diverse collaborative models including remote teaching, remote technical support and cross-center joint surgeries. This has gradually transformed robotic surgery into an advanced medical approach that can be widely promoted, standardized for training, and sustainably disseminated. Consequently, high-level surgical capabilities are continuously expanding from top-tier hospitals to regional centers and even primary hospitals.

Toumai's global market share continues to surge, establishing a replicable, scalable, and sustainably accelerating growth curve throughout the global markets. Leveraging the Group's in-depth presence across global multi-tiered healthcare systems and world-leading capabilities in remote technology, a comprehensive robotic surgery ecosystem is rapidly emerging. It is driven by top-tier global experts, deeply integrated with regional medical centers, and actively engaged by primary hospitals. Together, it seamlessly connects academic, technological, and clinical systems. As for now, the overseas market layout of Toumai has been broadly covered over 40 countries and regions across Asia, Europe, Africa, Oceania, and South America where it has gained recognition from local top-tier institutions. It has also achieved "multi-unit sales and multi-hospital installations" in 15 countries, establishing routine, networked, and scaled usage within mature healthcare systems across diverse global regions.

The board of directors of the Company wishes to remind the Shareholders and potential investors that the above information is unaudited and is based on preliminary internal information of the Group, which may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such information.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 24 December 2025

As at the date of this announcement, the executive Directors are Dr. Chao He and Mr. Yu Liu, the non-executive Directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive Directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.